TYK2 and inflammatory bowel disease: Several cytokines, including IFNs, IL‐6, IL‐12, IL‐23, IL‐21, and IL‐13, have been shown to act as mediators of pathological responses in UC patients [5] and many of these cytokines converge on the JAK‐STAT signaling pathway, including JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2), that have been explored as therapeutic targets in IBD [24].